Valbiotis Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Valbiotis's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 39.9% per year.
Belangrijke informatie
-14.6%
Groei van de winst
3.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 30.8% |
| Inkomstengroei | 39.9% |
| Rendement op eigen vermogen | -45.6% |
| Nettomarge | -243.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Valbiotis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 4 | -9 | 6 | 5 |
| 31 Mar 24 | 4 | -8 | 6 | 6 |
| 31 Dec 23 | 5 | -7 | 5 | 7 |
| 30 Sep 23 | 5 | -8 | 5 | 9 |
| 30 Jun 23 | 4 | -9 | 5 | 10 |
| 31 Mar 23 | 3 | -11 | 6 | 10 |
| 31 Dec 22 | 1 | -12 | 6 | 9 |
| 30 Sep 22 | 1 | -11 | 5 | 9 |
| 30 Jun 22 | 1 | -10 | 5 | 9 |
| 31 Mar 22 | 1 | -9 | 4 | 8 |
| 31 Dec 21 | 0 | -9 | 4 | 7 |
| 30 Sep 21 | 2 | -7 | 4 | 6 |
| 30 Jun 21 | 3 | -4 | 3 | 6 |
| 31 Mar 21 | 3 | -4 | 3 | 6 |
| 31 Dec 20 | 3 | -4 | 3 | 5 |
| 30 Sep 20 | 2 | -5 | 3 | 5 |
| 30 Jun 20 | 0 | -6 | 3 | 4 |
| 31 Mar 20 | 0 | -6 | 3 | 4 |
| 31 Dec 19 | 0 | -6 | 3 | 4 |
| 30 Sep 19 | 0 | -6 | 3 | 4 |
| 30 Jun 19 | 0 | -6 | 3 | 5 |
| 31 Mar 19 | 0 | -5 | 3 | 4 |
| 31 Dec 18 | 0 | -5 | 3 | 4 |
| 30 Sep 18 | 0 | -4 | 2 | 3 |
| 30 Jun 18 | 0 | -4 | 2 | 3 |
| 31 Mar 18 | 0 | -3 | 2 | 2 |
| 31 Dec 17 | 0 | -2 | 2 | 2 |
| 30 Sep 17 | 0 | -2 | 1 | 1 |
| 30 Jun 17 | 0 | -1 | 1 | 1 |
| 31 Mar 17 | 0 | -1 | 1 | 1 |
| 31 Dec 16 | 0 | -1 | 0 | 1 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: ALVAL is currently unprofitable.
Groeiende winstmarge: ALVAL is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ALVAL is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Versnelling van de groei: Unable to compare ALVAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ALVAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: ALVAL has a negative Return on Equity (-45.63%), as it is currently unprofitable.